EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue

Kiran Yadav, Prakash Chaudhary, Kalpana Ghimire, Sunil Mishra, Hyunji Lee, Dawon Bae, Jae-Hoon Chang, Byeong-Seon Jeong, Jung-Ae Kim iD

British Journal of Pharmacology · 2026-08 · 183 (15) · 4196-4214

DOI: 10.1111/bph.70455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 23.04.2026. Verfasst von Kiran Yadav und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antineoplastic Agents. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. RYK, an atypical receptor‐like tyrosine kinase, has emerged as a potential regulator of tumour signalling, but its role in PDAC remains poorly understood. This study aimed to evaluate the anticancer potential of BJ‐2412, a novel sunitinib analogue with RYK‐inhibitory activity, and to elucidate the functional relevance of RYK in PDAC. Experimental Approach BJ‐2412 was synthesized by introducing a 2,4‐dimethylpyridin‐3‐ol moiety into sunitinib. Its anticancer activity was assessed in PDAC cell lines and mouse tumour models. Mechanistic studies included RTK phosphorylation profiling, RYK knockdown via siRNA, co‐immunoprecipitation, immunoblotting of downstream effectors, and analyses of apoptosis, invasion, and macrophage phenotypes. Key Results BJ‐2412 inhibited RYK phosphorylation by disrupting its interaction with EGFR. While RYK knockdown and BJ‐2412 had minimal effects on proliferation, both impaired cancer cell survival, including that of cancer stem cells. We identified RYK as a GSK‐3β activator that antagonizes canonical WNT signalling and RTK‐mediated GSK‐3β inhibition. BJ‐2412 inactivated GSK‐3β and reduced Sonic Hedgehog (Shh) and GLI1 expression. BJ‐2412‐induced up‐regulation of WNT5A, cancer cell‐selective apoptosis, M1‐macrophage polarization, as well as down‐regulation of MMPs and CTSS, were reversed by recombinant Shh. Finally, BJ‐2412 suppressed tumour growth, invasion, and metastasis in xenograft and allograft mouse models. Conclusions and Implications These findings identify RYK as a GSK‐3β activator and a therapeutic vulnerability in PDAC. BJ‐2412 demonstrates therapeutic potential by targeting this pathway and remodelling the tumour microenvironment, offering a multifaceted strategy against PDAC progression and resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic AgentsIndolesSunitinibReceptor Protein-Tyrosine KinasesPyrrolesAnimalsHumansCell Line, TumorMiceApoptosisCell ProliferationMice, NudePhosphorylation

Stichwörter der Autor:innen

Sonic Hedgehog (Shh)glycogen synthase kinase‐3 beta (GSK‐3β)macrophage polarizationpancreatic ductal adenocarcinoma (PDAC)receptor tyrosine kinase (RTK)receptor‐like tyrosine kinase (RYK)

Substanzen

Glycogen Synthase Kinase 3 betaAntineoplastic AgentsIndolesSunitinibReceptor Protein-Tyrosine KinasesPyrroles

Autor:innen und Institutionen

  • College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
  • College of Pharmacy, Kyungsung University, Busan, Republic of Korea.

ORCID-Profile: Jung-Ae Kim

Förderung

  • National Research Foundation

Zitieren

APA

Yadav, K., Chaudhary, P., Ghimire, K., Mishra, S., Lee, H., Bae, D., Chang, J. H., Jeong, B. S., & Kim, J. A. (2026). Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue. British Journal of Pharmacology, 183(15), 4196-4214. https://doi.org/10.1111/bph.70455

Vancouver

Yadav K, Chaudhary P, Ghimire K, Mishra S, Lee H, Bae D, et al. Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue. British Journal of Pharmacology. 2026;183(15):4196-4214. doi:10.1111/bph.70455

BibTeX
@article{Yadav2026,
  author = {Yadav, Kiran and Chaudhary, Prakash and Ghimire, Kalpana and Mishra, Sunil and Lee, Hyunji and Bae, Dawon and Chang, Jae-Hoon and Jeong, Byeong-Seon and Kim, Jung-Ae},
  title = {Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4196--4214},
  doi = {10.1111/bph.70455}
}
Kostenlos starten →